Immediate Impact
52 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
2024 Standout
Works of Bruce Colwell being referenced
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Bruce Colwell | 138 | 20 | 36 | 33 | 16 | 170 | |
| C Verberne | 145 | 35 | 39 | 45 | 16 | 203 | |
| Aude Bardot | 124 | 31 | 38 | 16 | 16 | 219 | |
| Ondřej Májek | 159 | 32 | 56 | 82 | 11 | 209 | |
| Dominique Auby | 171 | 31 | 61 | 38 | 11 | 207 | |
| Alessandro Pastorino | 122 | 41 | 30 | 35 | 24 | 159 | |
| Katerina Shulman | 176 | 29 | 36 | 45 | 23 | 253 | |
| Stefania Eufemia Lutrino | 130 | 42 | 65 | 32 | 18 | 185 | |
| Sylvie Kirscher | 100 | 12 | 70 | 17 | 13 | 162 | |
| Dennis L. Sacdalan | 228 | 42 | 74 | 12 | 16 | 280 | |
| Daniele Pignataro | 100 | 24 | 111 | 19 | 18 | 216 |
All Works
Login with ORCID to disown or claim papers
Loading papers...